Loading…
PPBT
Purple Biotech Ltd
NASDAQ· Healthcare· Biotechnology· CUSIP 74638P307
$1.68+1.20%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $2.73M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$47.64
- ROE
- -111.13%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.54
- 52-week high
- $19.40
- 52-week low
- $1.16
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.8% over 5Y.
today you would have $1.65▼ -99.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $6.58 | $46.90 | $156.00 | $276.00 | |
| P/B | 1119.2x | 1259.2x | 738.1x | 1151.0x | 1087.4x |
| EPS | -$54.00 | -$44.16 | -$178.00 | -$240.00 | |
| ROE | -52.15% | -271.63% | -22.03% | -58.12% | -46.19% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NUWENuwellis, Inc. | $0.89 | 0.0x | — | — | — | $2.82M |
| CMNDClearmind Medicine Inc. | $1.76 | — | 0.2x | — | -114.61% | $2.61M |
| BIAFbioAffinity Technologies, Inc. | $4.87 | — | 0.6x | — | -1860.15% | $2.88M |
| PRFXPRF Technologies Ltd. | $0.96 |
About the company
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
- 10
- Rehovot, Israel
Company description provided by Yahoo Finance.